Geode Capital Management LLC boosted its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 3.1% during the first quarter, Holdings Channel reports. The firm owned 270,782 shares of the biopharmaceutical company’s stock after buying an additional 8,023 shares during the period. Geode Capital Management LLC’s holdings in Intra-Cellular Therapies were worth $4,400,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Nine Chapters Capital Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the first quarter worth $166,000. Highbridge Capital Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $166,000. American International Group Inc. raised its stake in shares of Intra-Cellular Therapies by 7.1% in the first quarter. American International Group Inc. now owns 21,130 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 1,396 shares during the period. Trexquant Investment LP purchased a new stake in shares of Intra-Cellular Therapies during the first quarter worth $384,000. Finally, Bank of Montreal Can raised its stake in shares of Intra-Cellular Therapies by 699.4% in the first quarter. Bank of Montreal Can now owns 29,105 shares of the biopharmaceutical company’s stock worth $473,000 after buying an additional 25,464 shares during the period. 66.66% of the stock is owned by institutional investors and hedge funds.

Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded down 1.64% on Tuesday, hitting $11.43. The stock had a trading volume of 50,289 shares. Intra-Cellular Therapies Inc. has a 12-month low of $7.85 and a 12-month high of $45.20. The stock has a 50 day moving average of $11.95 and a 200 day moving average of $12.52. The firm’s market cap is $496.34 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.33. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.03 million. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The firm’s revenue was down 52.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.71) earnings per share. Equities analysts predict that Intra-Cellular Therapies Inc. will post ($2.57) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Shares Bought by Geode Capital Management LLC” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/intra-cellular-therapies-inc-itci-shares-bought-by-geode-capital-management-llc/1491613.html.

A number of brokerages have weighed in on ITCI. BidaskClub lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday. Piper Jaffray Companies set a $10.00 target price on Intra-Cellular Therapies and gave the company a “hold” rating in a research report on Thursday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, August 9th. Finally, Leerink Swann lowered Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $29.00 to $10.00 in a research report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $24.14.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.